amlodipine besylate · Cmp Dev Llc · NDA 214439
Norliqva
Earliest generic entry, as listed
24 Feb 2041
Blocked by patent: US 11253474, US 11458095, US 11723866, US 12005141, US 12226528, US 12440441.
Listed patents · 6 unexpired
18 Orange Book listing rows for 6 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 11253474 | drug product, use U-3309, U-3310, U-3311 | 24 Feb 2041 |
| US 11253474 listing row | drug product, use U-3309 · sets the listed date | 24 Feb 2041 |
| US 11253474 listing row | drug product, use U-3310 · sets the listed date | 24 Feb 2041 |
| US 11253474 listing row | drug product, use U-3311 · sets the listed date | 24 Feb 2041 |
| US 11458095 | drug product, use U-3309, U-3310, U-3311 | 24 Feb 2041 |
| US 11458095 listing row | drug product, use U-3309 · sets the listed date | 24 Feb 2041 |
| US 11458095 listing row | drug product, use U-3310 · sets the listed date | 24 Feb 2041 |
| US 11458095 listing row | drug product, use U-3311 · sets the listed date | 24 Feb 2041 |
| US 11723866 | drug product, use U-3309, U-3310, U-3311 | 24 Feb 2041 |
| US 11723866 listing row | drug product, use U-3309 · sets the listed date | 24 Feb 2041 |
| US 11723866 listing row | drug product, use U-3310 · sets the listed date | 24 Feb 2041 |
| US 11723866 listing row | drug product, use U-3311 · sets the listed date | 24 Feb 2041 |
| US 12005141 | drug product, use U-3309, U-3310, U-3311 | 24 Feb 2041 |
| US 12005141 listing row | drug product, use U-3309 · sets the listed date | 24 Feb 2041 |
| US 12005141 listing row | drug product, use U-3310 · sets the listed date | 24 Feb 2041 |
| US 12005141 listing row | drug product, use U-3311 · sets the listed date | 24 Feb 2041 |
| US 12226528 | drug product, use U-3309, U-3310, U-3311 | 24 Feb 2041 |
| US 12226528 listing row | drug product, use U-3309 · sets the listed date | 24 Feb 2041 |
| US 12226528 listing row | drug product, use U-3310 · sets the listed date | 24 Feb 2041 |
| US 12226528 listing row | drug product, use U-3311 · sets the listed date | 24 Feb 2041 |
| US 12440441 | drug product, use U-3309, U-3310, U-3311 | 24 Feb 2041 |
| US 12440441 listing row | drug product, use U-3309 · sets the listed date | 24 Feb 2041 |
| US 12440441 listing row | drug product, use U-3310 · sets the listed date | 24 Feb 2041 |
| US 12440441 listing row | drug product, use U-3311 · sets the listed date | 24 Feb 2041 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214439 · 001 · RLD | solution, oral | EQ 1MG BASE/ML | 24 Feb 2041 |